Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is looking to accelerate their entry for product MPC-150-IM into the cardiovascular market after an successful set of on-going trials.
Their phase 3 and phase 2b trails are looking at moderate-to-severe and end stage advanced chronic heart failure patients.
Their product helps reduce damaging inflammation and builds cardiac repair.
Indications are that there are major unmet medical needs due to the high death rates despite existing therapies
The Data Monitoring Committee (DMC) recommended continuation of the trial without modification.
Shares in Mesoblast Limited
(ASX:MSB) down 1.88% to $1.57
